CN102088976B - 包含毒蕈碱性受体拮抗剂和β2-肾上腺素受体激动剂的药物产品 - Google Patents

包含毒蕈碱性受体拮抗剂和β2-肾上腺素受体激动剂的药物产品 Download PDF

Info

Publication number
CN102088976B
CN102088976B CN200980127403XA CN200980127403A CN102088976B CN 102088976 B CN102088976 B CN 102088976B CN 200980127403X A CN200980127403X A CN 200980127403XA CN 200980127403 A CN200980127403 A CN 200980127403A CN 102088976 B CN102088976 B CN 102088976B
Authority
CN
China
Prior art keywords
ethyl
phenyl
active component
bicyclo
nitrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980127403XA
Other languages
English (en)
Chinese (zh)
Other versions
CN102088976A (zh
Inventor
理查德·布尔
罗南·福特
安德鲁·马瑟
安东尼奥·梅特
凯瑟琳·威利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pulmagen Therapeutics Synergy Ltd
AstraZeneca AB
Original Assignee
Pulmagen Therapeutics Synergy Ltd
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0808710A external-priority patent/GB0808710D0/en
Priority claimed from GB0900563A external-priority patent/GB0900563D0/en
Application filed by Pulmagen Therapeutics Synergy Ltd, AstraZeneca AB filed Critical Pulmagen Therapeutics Synergy Ltd
Publication of CN102088976A publication Critical patent/CN102088976A/zh
Application granted granted Critical
Publication of CN102088976B publication Critical patent/CN102088976B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN200980127403XA 2008-05-13 2009-05-12 包含毒蕈碱性受体拮抗剂和β2-肾上腺素受体激动剂的药物产品 Expired - Fee Related CN102088976B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0808710A GB0808710D0 (en) 2008-05-13 2008-05-13 New combination 296
GB0808710.8 2008-05-13
GB0900563A GB0900563D0 (en) 2009-01-14 2009-01-14 New combination
GB0900563.8 2009-01-14
PCT/SE2009/050525 WO2009139708A1 (en) 2008-05-13 2009-05-12 PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A β2-ADRENOCEPTOR AGONIST

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2012104520326A Division CN102908624A (zh) 2008-05-13 2009-05-12 包含毒蕈碱性受体拮抗剂和β2-肾上腺素受体激动剂的药物产品

Publications (2)

Publication Number Publication Date
CN102088976A CN102088976A (zh) 2011-06-08
CN102088976B true CN102088976B (zh) 2012-12-26

Family

ID=41318921

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200980127403XA Expired - Fee Related CN102088976B (zh) 2008-05-13 2009-05-12 包含毒蕈碱性受体拮抗剂和β2-肾上腺素受体激动剂的药物产品
CN2012104520326A Pending CN102908624A (zh) 2008-05-13 2009-05-12 包含毒蕈碱性受体拮抗剂和β2-肾上腺素受体激动剂的药物产品

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2012104520326A Pending CN102908624A (zh) 2008-05-13 2009-05-12 包含毒蕈碱性受体拮抗剂和β2-肾上腺素受体激动剂的药物产品

Country Status (11)

Country Link
US (1) US20110190309A1 (https=)
EP (1) EP2315589A4 (https=)
JP (1) JP2011520877A (https=)
KR (1) KR20110010725A (https=)
CN (2) CN102088976B (https=)
AU (1) AU2009247021B2 (https=)
BR (1) BRPI0912657A2 (https=)
CA (1) CA2723909A1 (https=)
MX (1) MX2010012019A (https=)
RU (1) RU2010147881A (https=)
WO (1) WO2009139708A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200825084A (en) * 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
EA017627B1 (ru) 2008-05-13 2013-01-30 Астразенека Аб Хинуклидиновые производные в качестве антагонистов мускаринового м3 рецептора
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
KR101845257B1 (ko) 2011-02-07 2018-04-04 삼성전자주식회사 이미지 센서
JP2011195593A (ja) * 2011-06-30 2011-10-06 Astrazeneca Ab ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998004517A1 (en) * 1996-07-29 1998-02-05 Pharmacia & Upjohn Ab Arylcycloalkane carboxylic esters, their use, pharmaceutical compositions and preparation
WO2004096800A2 (en) * 2003-05-02 2004-11-11 Novartis Ag Quinuclidine derivatives binding to mucarinic m3 receptors
WO2006048225A1 (en) * 2004-11-02 2006-05-11 Novartis Ag Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists
WO2007018461A1 (en) * 2005-08-09 2007-02-15 Astrazeneca Ab Novel benzothiazolone derivatives
WO2007027134A1 (en) * 2005-08-29 2007-03-08 Astrazeneca Ab 7-(2-AMINO-1-HYDROXY-ETHYL)-4-HYDROXYBENZOTHIAZOL-2(3H)-ONE-DERIVATIVES AS β2 ADRENOCEPTOR AGONISTS

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL62140C (https=) * 1942-12-16
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
GR1001529B (el) * 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
US6223485B1 (en) * 1996-06-07 2001-05-01 Herman Miller, Inc. Wall panel system
US6613795B2 (en) * 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
JP2004532874A (ja) * 2001-04-03 2004-10-28 アリックス セラピューティクス 抗コリン作用性化合物および使用法
US7056916B2 (en) * 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
WO2008059239A1 (en) * 2006-11-14 2008-05-22 Astrazeneca Ab Novel compounds 514
TW200825084A (en) * 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
TW200833670A (en) * 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
GB0702456D0 (en) * 2007-02-08 2007-03-21 Astrazeneca Ab New combination
GB0702457D0 (en) * 2007-02-08 2007-03-21 Astrazeneca Ab New combination 666
GB0704000D0 (en) * 2007-03-01 2007-04-11 Astrazeneca Ab Salts 670
EA017627B1 (ru) * 2008-05-13 2013-01-30 Астразенека Аб Хинуклидиновые производные в качестве антагонистов мускаринового м3 рецептора
JP2011195593A (ja) * 2011-06-30 2011-10-06 Astrazeneca Ab ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998004517A1 (en) * 1996-07-29 1998-02-05 Pharmacia & Upjohn Ab Arylcycloalkane carboxylic esters, their use, pharmaceutical compositions and preparation
WO2004096800A2 (en) * 2003-05-02 2004-11-11 Novartis Ag Quinuclidine derivatives binding to mucarinic m3 receptors
WO2006048225A1 (en) * 2004-11-02 2006-05-11 Novartis Ag Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists
WO2007018461A1 (en) * 2005-08-09 2007-02-15 Astrazeneca Ab Novel benzothiazolone derivatives
WO2007027134A1 (en) * 2005-08-29 2007-03-08 Astrazeneca Ab 7-(2-AMINO-1-HYDROXY-ETHYL)-4-HYDROXYBENZOTHIAZOL-2(3H)-ONE-DERIVATIVES AS β2 ADRENOCEPTOR AGONISTS

Also Published As

Publication number Publication date
BRPI0912657A2 (pt) 2016-01-26
AU2009247021A1 (en) 2009-11-19
CN102908624A (zh) 2013-02-06
KR20110010725A (ko) 2011-02-07
EP2315589A1 (en) 2011-05-04
JP2011520877A (ja) 2011-07-21
EP2315589A4 (en) 2013-09-11
RU2010147881A (ru) 2012-06-20
WO2009139708A1 (en) 2009-11-19
AU2009247021B2 (en) 2012-06-07
MX2010012019A (es) 2011-03-04
CA2723909A1 (en) 2009-11-19
US20110190309A1 (en) 2011-08-04
CN102088976A (zh) 2011-06-08

Similar Documents

Publication Publication Date Title
RU2460527C2 (ru) Комбинация антагониста мускаринового рецептора и агониста бета-2-адренорецептора
AU2013365742B2 (en) Autotaxin inhibitors
CN102088976B (zh) 包含毒蕈碱性受体拮抗剂和β2-肾上腺素受体激动剂的药物产品
CN105051008B (zh) 胍基苯甲酸酯化合物
CN102202664A (zh) 包含毒蕈碱性受体拮抗剂和β2肾上腺素受体激动剂的药物产品
US20200190089A1 (en) Small molecule inhibitors of neutral sphingomyelinase 2 (nsmase2) for the treatment of neurodegenerative diseases
TW201803866A (zh) 新穎經取代之苯并咪唑，其製備方法，包含其之醫藥製劑及其用於製備藥劑之用途
WO2009154555A1 (en) Pharmaceutical product comprising a muscarinic receptor antagonist and a beta2-adrenoceptor agonist
WO2009139707A1 (en) Pharmaceutical product comprising a muscarinic receptor antagonist and a second active ingredient
CN102202665A (zh) 包含毒蕈碱性受体拮抗剂和另一种活性成分的药物产品

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20121226

Termination date: 20130512